Comparative effectiveness and safety of non-vitamin-K antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes

References

• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–1147.
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–162.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–844.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics – 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–e603.
   PubMed Web of Science ®Google Scholar
• Overvad TF Ilsko, Skjøth F, Lip GYH, et al. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke. 2015;46(8):2168–2174.
   PubMed Web of Science ®Google Scholar
• Fangel MV, Nielsen PB, Kristensen JK, et al. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus: a Danish cohort study. Circ Arrhythmia Electrophysiol. 2019;12:e007030.
   PubMed Web of Science ®Google Scholar
• Klem I, Wehinger C, Schneider B, et al. Diabetic atrial fibrillation patients: Mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev. 2003;19(4):320–328.
   PubMed Web of Science ®Google Scholar
• Karayiannides S, Lundman P, Friberg L, et al. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: a nationwide report. Diabetes Vasc Dis Res. 2018;15(1):31–38.
   PubMed Web of Science ®Google Scholar
• Polovina M, Lund LH, Đikić D, et al. Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation. Eur J Heart Fail. 2020;22(1):113–125.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359–364.
   PubMed Web of Science ®Google Scholar
• Huxley RR, Alonso A, Lopez FL, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis risk in communities study. Heart. 2012;98(2):133–138.
   PubMed Web of Science ®Google Scholar
• Koektuerk B, Aksoy M, Horlitz M, et al. Role of diabetes in heart rhythm disorders. World J Diabetes. 2016;7(3):45–49.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Gulløv A L, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 1999;159(12):1322–1328.
   PubMedGoogle Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Skjøth F, Nielsen PB, et al. Effectiveness and safety of standard-dose nonvitamin K antagonist oral anticoagulants and warfarin among patients with atrial fibrillation with a single stroke risk factor. JAMA Cardiol. 2017;2(8):872–881.
   PubMed Web of Science ®Google Scholar
• Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace. 2015;17(2):187–193.
   PubMed Web of Science ®Google Scholar
• Forslund T, Wettermark B, Andersen M, et al. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2018;20(3):420–428.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Peacock WF, Bunz TJ, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48(8):2142–2149.
   PubMed Web of Science ®Google Scholar
• Noseworthy P, Yao X, Sangaralingham LR, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;67:692.
   Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:1–19.
   Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, Lewis BS, Lopes RD, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):86–94.
   PubMed Web of Science ®Google Scholar
• Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. Int J Cardiol. 2015;196:127–131.
   PubMed Web of Science ®Google Scholar
• Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the rivaroxaban once-daily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibril. Am Heart J. 2015;170(4):675–682.
   PubMed Web of Science ®Google Scholar
• Sharma M, Cornelius R, Patel P, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015;132(3):194–204.
   PubMed Web of Science ®Google Scholar
• Sadlon AH, Tsakiris DA. Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions. Swiss Med Wkly. 2016;146:w14356.
   PubMed Web of Science ®Google Scholar
• Deng K, Cheng J, Rao S, et al. Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med (Lausanne). 2020;7:107.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33:1595–1604.
   PubMed Web of Science ®Google Scholar
• Kailas SD, Thambuluru SR. Efficacy and safety of direct oral anticoagulants compared to warfarin in prevention of thromboembolic events among elderly patients with atrial fibrillation. Cureus. 2016;8:3–9.
   Web of Science ®Google Scholar
• Xian Y, Xu H, O’Brien EC, et al. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol. 2019;76(10):1192.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11.
   PubMed Web of Science ®Google Scholar
• Shroff GR, Solid CA, Bloomgarden Z, et al. Temporal trends in ischemic stroke and anticoagulation therapy for non-valvular atrial fibrillation: effect of diabetes. J Diabetes. 2017;9(2):115–122.
   PubMed Web of Science ®Google Scholar
• Staszewsky L, Cortesi L, Baviera M, et al. Diabetes mellitus as risk factor for atrial fibrillation hospitalization: incidence and outcomes over nine years in a region of Northern Italy. Diabetes Res Clin Pract. 2015;109:0–8.
   Web of Science ®Google Scholar
• Chan YH, Chuang C, Chan CC, et al. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. Cardiovasc Diabetol. 2020;19:1–14.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Hsu PF, Sung SH, et al. Is there a preferred stroke prevention strategy for diabetic patients with non-valvular atrial fibrillation? Comparing warfarin, dabigatran and rivaroxaban. Thromb Haemost. 2018;118:72–81.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian AV, Kang AL, et al. Effectiveness and safety of oral anticoagulants in patients with nonvalvular atrial fibrillation and diabetes mellitus. Mayo Clin Proc. 2020;95(5):929–943.
   PubMed Web of Science ®Google Scholar
• Li G, Lip GYH, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34(2):173–190.
   PubMed Web of Science ®Google Scholar
• Jacobs V, May HT, Bair TL, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol. 2016;118(2):210–214.
   PubMed Web of Science ®Google Scholar
• What’s Medicare? Medicare [Internet] [cited 2020 May 18]. Available from: https://www.medicare.gov/what-medicare-covers/your-medicare-coverage-choices/whats-medicare
   Google Scholar
• Jensen P, Johnson K, Floyd J, et al. Identifying atrial fibrillation from electronic medical data: a systematic review. Pharmacoepidemiol Drug Saf. 2012;21:141–147.
   PubMed Web of Science ®Google Scholar
• Khokhar B, Jette N, Metcalfe A, et al. Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations. BMJ Open. 2016;6(8):e009952.
   PubMed Web of Science ®Google Scholar
• Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114:1290–1298.
   PubMed Web of Science ®Google Scholar
• Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114:1277–1289.
   PubMed Web of Science ®Google Scholar
• Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(9):968–978.
   PubMed Web of Science ®Google Scholar
• Thigpen JL, Dillon C, Forster KB, et al. Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8(1):8–14.
   PubMed Web of Science ®Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560–566.
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services DoHaHS. Chronic conditions data warehouse [Internet] [cited 2020 Nov 16]. Available from: https://www2.ccwdata.org/web/guest/condition-categories
   Google Scholar
• Kocis PT, Liu G, Makenbaeva D, et al. Use of chronic medications among patients with non-valvular atrial fibrillation. Drugs Real World Outcomes. 2016;3(2):165–173.
   PubMedGoogle Scholar
• Yang Y, Zhang Z, Ng CY, et al. Meta-analysis of CHADS2 score in predicting atrial fibrillation. Am J Cardiol. 2015;116(4):554–562.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F, Manzano-Fernández S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-vasc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–2204.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2011;57(2):173–180.
   PubMed Web of Science ®Google Scholar
• Bergstralh E, Kosanke J. Mayo clinic research – division of biomedical statistics and informatics. Locally Written SAS Macros [Internet] [cited 2020 May 18]. Available from: http://bioinformaticstools.mayo.edu/research/gmatch/
   Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107.
   PubMed Web of Science ®Google Scholar
• Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–526.
   Web of Science ®Google Scholar
• Granger CB, Armaganijan LV. Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism? Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125(1):159–164.
   PubMed Web of Science ®Google Scholar
• Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non-vitamin K antagonist oral anticoagulants: a review. JAMA Cardiol. 2017;2(4):442–448.
   PubMed Web of Science ®Google Scholar
• Yamagishi S-I. Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation. Cardiovasc Diabetol. 2019;18:12.
   PubMed Web of Science ®Google Scholar
• Bell DSH, Goncalves E. Should we still be utilizing warfarin in the type 2 diabetic patient? Diabetes Obes Metab. 2018;20(10):2327–2329.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke. 2015;46(8):2175–2182.
   PubMed Web of Science ®Google Scholar
• Chang SH, Chou IJ, Yeh YH, et al. Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318(13):1250–1259.
   PubMed Web of Science ®Google Scholar
• Forbes HL, Polasek TM. Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8(10):319–328.
   PubMed Web of Science ®Google Scholar
• Patti G, Di Gioia G, Cavallari I, et al. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes Metab Res Rev. 2017;33(3):e2876.
   Web of Science ®Google Scholar
• Reiffel JA. Stroke rate variation and anticoagulation benefit in atrial fibrillation. Ann Intern Med. 2019;170(11):818.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2013;167(4):1237–1241.
   PubMed Web of Science ®Google Scholar
• Mitchell A, Watson MC, Welsh T, et al. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med. 2019;8:554.
   Web of Science ®Google Scholar
• Peacock WF, Tamayo S, Sicignano N, et al. Comparison of the incidence of major bleeding with rivaroxaban use among nonvalvular atrial fibrillation patients with versus without diabetes mellitus. Am J Cardiol. 2017;119(5):753–759.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Bunz TJ, Eriksson D, et al. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. Diabet Med. 2018;35(8):1105–1110.
   PubMed Web of Science ®Google Scholar
• Tayebjee MH, Lim HS, MacFadyen RJ, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year’s cardiovascular risk reduction therapy. Diabetes Care. 2004;27(8):2049–2051.
   PubMed Web of Science ®Google Scholar
• Lim HS, MacFadyen RJ, Lip GYH. Diabetes mellitus, the renin–angiotensin–aldosterone system, and the heart. Arch Intern Med. 2004;164(16):1737–1748.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140:e125–e151.
   PubMed Web of Science ®Google Scholar